Can Ozempic Make You Go Blind? Eye Doctor Explains
Spencer Nadolsky, DOPublished on July 11, 2025
Summary authored by editor@wellifi.com
TLDR Summary
This podcast episode discusses macular degeneration, its symptoms, risk factors, and recent concerns regarding GLP-1 receptor agonists. Experts emphasize the importance of understanding these risks and the protective measures available to maintain eye health.
Key Points
- Macular degeneration is primarily a concern for those over 50, leading to central vision loss.
- Two main types of macular degeneration: Dry (drusen buildup) and Wet (abnormal blood vessel growth).
- Recent studies suggest a potential link between GLP-1 receptor agonists and increased risk of neovascular macular degeneration, but actual risk remains low.
- Protective measures include vitamins and lifestyle changes to mitigate risks associated with macular degeneration.
Understanding Macular Degeneration: Insights from Dr. Spencer Nadolsky and Dr. Buger
Welcome back to the Docs Who Lift podcast! I'm your host, Dr. Spencer, and today I’m joined by my brother and our special guest, Dr. Buger. We’re diving into an important topic related to eye health—macular degeneration—and discussing recent findings that have sparked concern among those taking GLP-1 receptor agonists.
What is Macular Degeneration?
Macular degeneration is a progressive eye condition that primarily affects older adults, leading to vision loss. Dr. Buger explains that it arises from a buildup of waste material beneath the retina, which can lead to two main types:
- Dry Macular Degeneration: Characterized by the presence of drusen, small yellowish deposits under the retina, causing blurriness and distortion in vision.
- Wet Macular Degeneration: Involves the growth of abnormal blood vessels that leak fluid, leading to more severe vision loss.
Symptoms and Risk Factors
Symptoms often include central vision loss, making it difficult to read or recognize faces. The risk factors include:
- Age: Increased risk for those over 50.
- Genetics: Family history of the condition.
- Gender: Higher prevalence in women.
- Ethnicity: More common in individuals of Scandinavian descent.
- Environmental factors: Smoking increases risk significantly.
Recent Studies and GLP-1 Agonists
Recently, a report in JAMA raised concerns about the link between GLP-1 receptor agonists and an increased risk of neovascular macular degeneration. However, Dr. Buger emphasizes the importance of scrutinizing these studies closely, as they often fail to account for underlying conditions that may predispose individuals to macular degeneration.
He notes that while the absolute risk increase may seem alarming, the actual percentage remains very small, and many other factors contribute to the development of this eye condition.
Protective Measures
Dr. Buger discusses that there are indeed protective measures available for those at risk of macular degeneration:
- Vitamins: Over-the-counter vitamins can help slow down the progression of the disease.
- Lifestyle Changes: Addressing metabolic syndrome through diet and exercise can significantly reduce risk.
Conclusion
This conversation highlights the importance of understanding macular degeneration and the nuanced relationship between medications like GLP-1 agonists and eye health. For anyone concerned about the risk of blindness due to these medications, it’s crucial to have informed discussions with healthcare providers.
Don't forget to share this podcast with anyone who might benefit from this information!
This podcast is for entertainment and educational purposes only. It should not be considered professional medical advice.